A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Berenson
James R
JR
Institute for Myeloma and Bone Cancer Research and Oncotherapeutics, Los Angeles, CA, USA.
Swift
Regina A
RA
Ferretti
Delina
D
Purner
Matthew B
MB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
D001152:Arsenicals; D010087:Oxides; D001205:Ascorbic Acid; D008558:Melphalan; D000077237:Arsenic Trioxide